title: Present development concerning antimalarial activity of phospholipid metabolism inhibitors with special reference to in vivo activity.
abstract: The systematic screening of more than 250 molecules against Plasmodium falciparum in vitro has previously shown that interfering with phospholipid metabolism is lethal to the malaria parasite. These compounds act by impairing choline transport in infected erythrocytes, resulting in phosphatidylcholine de novo biosynthesis inhibition. A thorough study was carried out with the leader compound G25, whose in vitro IC50 is 0.6 nM. It was very specific to mature parasites (trophozoïtes) as determined in vitro with P. falciparum and in vivo with P. chabaudi -infected mice. This specificity corresponds to the most intense phase of phospholipid biosynthesis activity during the parasite cycle, thus corroborating the mechanism of action. The in vivo antimalarial activity (ED50) against P. chabaudi was 0.03 mg/kg, and a similar sensitivity was obtained with P. vinckei petteri, when the drug was intraperitoneally administered in a 4 day suppressive test. In contrast, P. berghei was revealed as less sensitive (3- to 20-fold, depending on the P. berghei-strain). This difference in activity could result either from the degree of synchronism of every strain, their invasion preference for mature or immature red blood cells or from an intrinsically lower sensitivity of the P. berghei strain to G25. Irrespective of the mode of administration, G25 had the same therapeutic index (lethal dose 50 (LD50)/ED50) but the dose to obtain antimalarial activity after oral treatment was 100-fold higher than after intraperitoneal (or subcutaneous) administration. This must be related to the low intestinal absorption of these kind of compounds.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: CNRS URA 1856, Université Montpellier II, France.
authors.forename: M L
authors.initials: ML
authors.lastname: Ancelin
authors.forename: H J
authors.initials: HJ
authors.lastname: Vial
authors.forename: M
authors.initials: M
authors.lastname: Calas
authors.forename: L
authors.initials: L
authors.lastname: Giral
authors.forename: G
authors.initials: G
authors.lastname: Piquet
authors.forename: E
authors.initials: E
authors.lastname: Rubi
authors.forename: A
authors.initials: A
authors.lastname: Thomas
authors.forename: W
authors.initials: W
authors.lastname: Peters
authors.forename: C
authors.initials: C
authors.lastname: Slomianny
authors.forename: S
authors.initials: S
authors.lastname: Herrera
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D002794:Choline; D004351:Drug Resistance; D006790:Host-Parasite Interactions; D006801:Humans; D007928:Lethal Dose 50; D008288:Malaria / Q000517:prevention & control*; D051379:Mice; D010743:Phospholipids / Q000037:antagonists & inhibitors / Q000378:metabolism; D010961:Plasmodium / Q000187:drug effects*
chemical_list: D000962:Antimalarials; D010743:Phospholipids; D002794:Choline